What Is Setmelanotide?

1. How does setmelanotide work?

In the hypothalamus, the leptin-melanocortin pathway connects leptin, a hormone made by fat tissue, to the MC4 receptor. The signal runs through the leptin receptor (LEPR) and through pro-opiomelanocortin (POMC), the precursor protein of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH then switches on MC4 receptors, which reduces hunger.

If any link in that chain fails, the “enough food” message never arrives. The conditions setmelanotide treats are failures at different points:

• LEPR deficiency: the receptor that reads leptin does not work.
• POMC or PCSK1 deficiency: the body cannot produce alpha-MSH.
• Bardet-Biedl syndrome (BBS): an inherited disorder of cilia, tiny antenna-like structures on cells, that may disrupt signaling in this pathway, as described in Haqq and colleagues’ trial report.
• Acquired hypothalamic obesity: the hypothalamus is injured, for example by a tumor in that region or by the surgery or radiation used to treat it, as described in Roth and colleagues’ phase 2 report.

Setmelanotide skips past the broken steps and activates the MC4 receptor directly. The Imcivree prescribing information reports roughly 20-fold weaker activity at the MC3 and MC1 receptors. MC1 sits on pigment cells, which is why skin darkening is so common.

How is this different from semaglutide and tirzepatide?

The label’s own limits make the practical point. Setmelanotide is not indicated for general (polygenic) obesity, the common form shaped by many genes plus environment, and the FDA states it would not be expected to work there. For most people asking about weight-loss medicines, the relevant comparisons are among GLP-1-based drugs instead.

Relation to other melanocortin peptides

Setmelanotide belongs to the same family as Melanotan II and PT-141 (bremelanotide), which also act on melanocortin receptors and are discussed for tanning and sexual function. Setmelanotide’s label describes it as MC4-focused, with weaker MC1 and MC3 action, yet skin darkening and spontaneous erections still appear among its common reactions. Evidence for one of these peptides does not carry over to the others.

2. What did the clinical trials find?

Setmelanotide’s trials are small by obesity-drug standards because the conditions are rare. Several were single-arm, meaning everyone received the drug with no parallel placebo group.

Acquired hypothalamic obesity: the TRANSCEND trial

TRANSCEND was a randomized, double-blind, placebo-controlled phase 3 trial with 52 weeks of treatment after dose escalation. The NEJM publication by Miller and colleagues reported 120 participants aged 4 to 66, randomized 2:1. The FDA label analyzes a larger group of 142 from the same trial:

The published analysis was similar: BMI dropped 16.5% on setmelanotide and rose 3.3% on placebo. Serious adverse events were more frequent with the drug, at 28% versus 8%. The hunger-score difference was smaller than the weight result, at about 0.8 points. Before TRANSCEND, a 16-week open-label phase 2 study of 18 patients aged 6 to 40 had reported a mean BMI reduction of 15%.

POMC, PCSK1 and LEPR deficiency

The first two treated patients, both with POMC deficiency, lost 51.0 kg over 42 weeks and 20.5 kg over 12 weeks in Kühnen and colleagues’ 2016 report. Two matching single-arm phase 3 trials followed, reported by Clément and colleagues:

These trials built in a blinded withdrawal test. Responders received 4 weeks of drug and then 4 weeks of placebo. Off the drug, they regained about 5.5 kg (POMC/PCSK1) and 5.0 kg (LEPR) on average within those 4 weeks, then lost weight again after restarting.

Bardet-Biedl syndrome

The BBS trial combined a 14-week placebo-controlled phase with 52 weeks of open-label treatment. In the published primary group, 32.3% of patients aged 12 and up lost at least 10% of body weight by 52 weeks (Haqq and colleagues). Results in Alström syndrome, a related condition, were inconclusive, and it is not an approved use.

Children aged 2 to 5

The open-label VENTURE trial treated 12 young children with POMC or LEPR deficiency or BBS for a year. Mean BMI fell 18% overall, 26% in the POMC/LEPR group and 10% in the BBS group, according to Argente and colleagues. With only a handful of children per condition and no control group, these numbers are rough estimates.

Does it do anything in ordinary obesity?

Very little human evidence exists. In a crossover study by Chen and colleagues, 12 adults with obesity but none of the target conditions received a continuous infusion of setmelanotide (1 mg per 24 hours) or placebo for 72 hours each. Resting energy expenditure rose 6.4%, about 111 kcal per day, fat burning increased, and heart rate and blood pressure did not change. A 3-day study cannot show weight loss, and the label says safety and effectiveness in this population are not established.

3. Is setmelanotide FDA-approved, and for whom?

Yes, for a narrow set of conditions. The US indications grew in four steps:

For POMC, PCSK1 or LEPR deficiency, a genetic test must show variants interpreted as pathogenic, likely pathogenic or of uncertain significance. Variants classed as benign or likely benign do not qualify, and neither do other genetic syndromes. The EMA has authorized Imcivree in the EU since July 16, 2021, and lists indications covering the same three groups of conditions.

In the US it is a prescription drug and is not among the anabolic steroids listed in Schedule III. It is not named on the WADA 2026 Prohibited List.

4. How is setmelanotide dosed?

The label calls for one subcutaneous injection a day at the start of the day, with or without food, from a 10 mg/mL multiple-dose vial. Like many obesity drugs, it starts low and steps up every 2 weeks if tolerated, a process explained in the dose titration guide.

Kidney function changes the plan. The label does not recommend the drug in end-stage kidney disease, or in acquired hypothalamic obesity with severe renal impairment, and it lowers doses for the other indications when impairment is severe. These are prescriber decisions tied to a confirmed diagnosis, not a template for anyone else.

5. How long does setmelanotide last in the body?

From the label’s pharmacology section:

An 11-hour half-life explains the daily schedule, in contrast with the weekly dosing of semaglutide or tirzepatide. Exposure rises as kidney function declines, reaching 86% to 96% higher total exposure in severe impairment, and children aged 6 to under 12 had about 88% higher exposure than adults on the same dose. The half-life tracking guide explains how these figures translate into rising and falling levels between doses.

6. What are the side effects and risks?

The label has no boxed warning. Its one contraindication is a previous serious allergic reaction to setmelanotide or an ingredient.

In the open-label genetic-deficiency trials, injection site reactions affected 96% and depression 26%. In the BBS trial’s placebo-controlled phase, skin darkening occurred in 67% on the drug and none on placebo.

The label’s warnings, in plain terms:

• Skin and moles. Darkening can be widespread or patchy and reverses after stopping. Because moles can darken or newly appear, a full-body skin exam is advised before and during treatment.
• Sexual effects. Spontaneous or more frequent erections occurred in males, and sexual adverse reactions also occurred in females. An erection lasting over 4 hours needs emergency care.
• Mood. Depression and suicidal thoughts occurred, with suicidal ideation in 11% of the 27 patients in the genetic-deficiency trials. A history of depression may raise the risk.
• Allergic reactions. Serious reactions, including anaphylaxis, have been reported after marketing.
• Adrenal crisis (hypothalamic obesity). In patients with secondary adrenal insufficiency, serious adrenal-crisis events occurred in 5% on drug and none on placebo.
• Sodium imbalance (hypothalamic obesity). In patients with arginine vasopressin deficiency, also called central diabetes insipidus, low sodium occurred in 6% versus 2% on placebo.

The label advises stopping when pregnancy is recognized unless the benefit outweighs the risk, and does not recommend use while breastfeeding. Over 52 weeks or more, 1.6% of patients developed antibodies to setmelanotide, with unknown clinical meaning.

7. Interactions, GLP-1 combinations and monitoring

The label judged the risk of liver-enzyme (CYP), transporter or protein-binding interactions to be low, but no clinical interaction studies were run. None of the trials reviewed here tested setmelanotide together with semaglutide, tirzepatide or another GLP-1-based drug, so there are no data on extra weight loss or stacked side effects. Nausea and vomiting are common with both drug types, which matters if a specialist ever combines them.

The label builds several checks into treatment:

8. What can you meaningfully track on setmelanotide?

The trials measured percent change in BMI or body weight and a daily hunger score, so those are the most comparable personal measures. Because the withdrawal data showed regain within weeks, a missed-dose log next to weekly weight helps a clinician tell a true plateau from a gap in treatment. The missed dose tool covers general timing questions, but the label’s instructions take priority.

The published results report BMI and weight rather than body composition, so they do not show how much of the loss was fat versus muscle. The concerns raised in the GLP-1 muscle loss guide have not been tested for setmelanotide in the sources here. Photos or notes on skin color and moles, mood check-ins and injection site reactions are all worth recording, since each maps to a label warning. A peptide tracker keeps these alongside doses and dates, which makes the record easier to review with the prescribing team.

9. Setmelanotide FAQ

• Is setmelanotide a GLP-1 drug?

  No. Setmelanotide activates the melanocortin 4 (MC4) receptor in the hypothalamus. Semaglutide and tirzepatide act on incretin hormone receptors. Both classes reduce appetite, but they work at different points and are approved for different people.

• Can setmelanotide be used for regular weight loss?

  No. The FDA label states it is not indicated, and would not be expected to be effective, in general (polygenic) obesity or in genetic syndromes other than those listed. The only data in people without these conditions come from a 72-hour metabolic study in 12 adults.

• Who is setmelanotide approved for?

  In the US: people aged 4 and up with acquired hypothalamic obesity, and people aged 2 and up with Bardet-Biedl syndrome or with POMC, PCSK1 or LEPR deficiency confirmed by genetic testing. The EU authorization lists the same three groups of conditions.

• What are the side effects of setmelanotide?

  The label's most common reactions include skin darkening, injection site reactions, nausea, vomiting, headache, diarrhea, abdominal pain, depression and spontaneous penile erections. It also warns about new or darkening moles, suicidal thoughts, serious allergic reactions and, in hypothalamic obesity, adrenal crisis and sodium imbalance.

• Does the skin darkening from setmelanotide go away?

  According to the label, the darkening reverses after the drug is stopped. The label recommends a full-body skin exam before treatment and periodically during it, because moles can also darken or appear.

• How long does setmelanotide stay in your system?

  The label gives an effective half-life of about 11 hours, with peak levels around 8 hours after an injection and steady state within 2 days of daily dosing. Exposure is higher with reduced kidney function and in younger children.

• Can setmelanotide be used with semaglutide or tirzepatide?

  The trials and label reviewed here did not test that combination, so there is no evidence on added benefit or combined side effects. Any decision belongs with the prescribing specialist. Both drug types can cause nausea and vomiting, which is worth tracking if a clinician combines them.

• Is setmelanotide banned in sport?

  It is not named on the WADA 2026 Prohibited List. In the US it is a prescription drug and is not a controlled substance.

10. Sources